Sample preparation is a technique that is used for converting biological and chemical products into a form that can be placed directly in analytical instruments for analysis. The different types of products in sample preparation are sample preparation instruments, consumables, and sample preparation kits. Sample preparation instrument market includes extraction systems, workstations, automated evaporation systems, liquid handling instruments, and other sample preparation instruments. It is used in proteomics, genomics, epigenomics, and others and is implemented in various sectors such as pharmaceuticals, biotechnology, molecular diagnostics, and others. The sample preparation market research report is one of a series of new reports from The Business Research Company that provides sample preparation market statistics, including sample preparation industry global market size, regional shares, competitors with a sample preparation market share, detailed sample preparation market segments, market trends and opportunities, and any further data you may need to thrive in the sample preparation industry. This sample preparation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global sample preparation market size grew from $8.11 billion in 2022 to $8.66 billion in 2023 at a compound annual growth rate (CAGR) of 6.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The sample preparation market size is expected to grow to $10.87 billion in 2027 at a CAGR of 5.8%. An increase in R&D spending in pharmaceuticals is expected to drive the growth of the sample preparation market in the coming years. Although pharmaceutical analyses have been performed using a variety of highly efficient analytical instruments, most sample preparation procedures are required to extract and isolate the analytes of interest from these complex matrixes because most analytical instruments cannot handle the matrix directly. The advancement of sample preparation is critical in pharmaceutical analysis, with the ultimate goal of isolating and purifying the analyte from complex matrixes. According to the National Centre for Biotechnology Information, a US-based government organization, pharmaceutical spending increased by 7.7% in 2021 to reach $576.9 billion in the US. In 2022, they forecast rises in prescription drug spending of 4.0% to 6.0% overall, 7.0% to 9.0% in clinics, and 3.0% to 5.0% in hospitals. Therefore, the increase in R&D spending in pharmaceuticals propels the growth of the sample preparation market. Players in the sample preparation industry are increasingly developing automated sample preparation systems. An automated sample preparation system uses robotics to manage the number of liquids such as reagents, specimen samples to prepare the samples for analysis and testing. These systems are integrated with software and spectrometric instruments for easy analysis of samples. For instance, in October 2020, PerkinElmer, Inc., a US-based company that enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare launched a fully automated liquid handling sample preparation and LC/MS/MS analysis workflow for testing pesticide residue in hemp and cannabis flower sample. In addition to cannabis-optimized reagents and sample prep consumables, the new end-to-end package includes proprietary cannabis SOPs and cloud-based tracking and reporting tools. In August 2021, Pacific Biosciences, a US-based biotechnology company, acquired Circulomics Inc. for an undisclosed amount. Through this acquisition, the Circulomics team will increase Pacific Biosciences' capacity for extraction and sample preparation and provide a simpler route toward an end-to-end automated workflow. Circulomics Inc. is a US-based biotechnology startup dedicated to providing highly distinctive sample preparation solutions supporting genomic workflows. Major players in the sample preparation market are Agilent Technologies, Bio-Rad Laboratories, Danaher Corporation, Illumina, Qiagen NV, PerkinElmer, F. Hoffmann-La Roche, Tecan Group Ltd., Hamilton Company, Norgen Biotek Corporation, Waters Corporation, Promega Corporation, and Biotage AB. North America was the largest region in the sample preparation market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sample preparation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the sample preparation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The sample preparation market consists of sales of solid phase extraction products, and automated instrumentation. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global sample preparation market is segmented - 1) By Product: Sample Preparation Instruments, Consumables, Sample Preparation Kit 2) By Application: Proteomics, Genomics, Epigenomics, Other Applications 3) By End User: Pharmaceutical, Biotechnology, Molecular Diagnostics, Other End Users

Protein expression is a process in which proteins are synthesized, modified, regulated, and controlled in living organisms according to the host cell. Protein expression in the context of protein research can now also refer to the application of lab procedures necessary for protein production. The main product types for protein expression are reagents, competent cells, expression vectors, services, and instruments. A reagent is a substance or compound that is added to a system in order to produce a chemical reaction or to determine whether or not a reaction occurred. The various forms of protein expression include yeast expression, mammalian expression, algae expression, insect expression, bacterial expression, and cell-free expression that are used for therapeutic, industrial, and research applications. The different end users involve pharmaceutical and biotechnology companies, academic research, and contract research organizations. The protein expression market research report is one of a series of new reports from The Business Research Company that provides protein expression market statistics, including protein expression industry global market size, regional shares, competitors with a protein expression market share, detailed protein expression market segments, market trends and opportunities, and any further data you may need to thrive in the protein expression industry. This protein expression market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global protein expression market will grow from $2.87 billion in 2022 to $3.19 billion in 2023 at a compound annual growth rate (CAGR) of 11.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global protein expression market is expected to grow to $4.96 billion in 2027 at a CAGR of 11.6%. An increase in demand for biologics to counter various genetic disorders and chronic diseases is one the major factors driving the research and sales of protein expression market. Biologics is a medicine produced from living organisms or contains components of living organisms such as protein, tissue, genes, allergens, cells, blood components, blood, and vaccines. The increasing use of biologics (therapeutic protein and others) to cure chronic diseases such as cancer, cardiovascular conditions and genetic disorders, is increasing the demand for protein expression devices and equipment. According to the World Health Organization, chronic disease prevalence rose by 57% globally, in the year 2020. Hence the rising demand for biologics is driving the protein expression market. For instance, according to an article published by Chemistry World, analysts stated that the biologics market hold a market share of more than a quarter of the entire pharmaceutical market in 2020. The global biologics market is expected to grow at 14.7% during 2021-2023. Government regulations related to protein therapeutics and the production of biologics may hinder the protein expression market growth. Government regulations on biologics to undergo rigorous preclinical and clinical trials prior to regulatory approval, and time-consuming process for approval of biologics with regards to health and the safety of any individual are restraining the market growth. Marketing and distribution of biologics including insulin, hormones, therapeutic antibodies, and vaccines depends upon the successful completion of clinical trials, which is a long, expensive, and uncertain process. According to FDA, for an approval of new biologic, Under the regulations (21 CFR 314.81(b)(2)(vii) and 601.70, a clinical trial approval usually takes 10- 12 months where firms are required to submit a report annually on the status of clinical safety, clinical efficiency, clinical pharmacology, and nonclinical toxicology study. Companies in the industry are increasingly adopting Microfluidics technology to enhance protein expression tests in order to reduce the time, cost, labor, and increase in the accuracy and performance. The microfluidics technology effectively analyzes biological samples than the traditional (macroscale) instruments. Microfluidics technology is used to measure the expression of proteins on cells and optimizes the output to generate results regarding protein expression. Therapeutics-on-a-chip (TOC) uses microfluidic platform and is able to synthesize proteins in a point-of-care setting to reduce cost associated with storage and transportation of therapeutic proteins. For instance, companies such as MissionBio, NanoCellect Biomedical, RainDance Technologies and Sphere fluidics have implemented this technology in protein expression test. The Protein Expression market in the U.S. is governed by the Food and Drug Administration (FDA) which lays down a series of guidelines for the manufacturers and retailers of this industry. Within FDA, Centre for Drug Evaluation and research (CDER) regulates biological products under FDA 101 which includes gene therapy products and vaccines. These regulations ensure the quality, safety, and efficacy of biological therapeutics products, and speed up innovations that make these products safer, and effective. The US FDA announced a fast-track initiative to review its drugs and biologics policy to speed the availability of therapies to patients with serious conditions, orphan drugs for rare disease, while preserving the safety and efficacy standards. FDA also removed a rule (Section 610.21 of the FDA code) that specified minimal potency limits for certain antibodies and antigens. The European Medicines Agency has also introduced policies that include a provision to waive the scientific advice fee, which encourages more academic groups and small companies to propose candidates for biologics. Major players in the protein expression market are Agilent Technologies, Bio-Rad Laboratories, Thermo Fisher Scientific Inc., New England Biolabs, Promega Corporation, Qiagen, Takara Bio, Merck KGaA, Genscript Biotech Corporation, Life Technologies Corporation, Sigma-Aldrich Corporation, Lucigen Corporation, Synthetic Genomics Inc., Becton, Dickinson & Company, Lonza Group Ltd., Accelagen Inc., Geneva Biotech, Viva Biotech, Becton, Dickinson & Company, Sengenics, ARTES Biotechnology GmbH, Addgene Inc., Profacgen, ProteoGenix, Peak Proteins Ltd., Domainex Ltd., Jena Bioscience GmbH, EMD Millipore, and Oxford Expression Technologies Ltd. North America was the largest region in the protein expression market in 2022. Western Europe was the second largest region in the global protein expression market. The regions covered in the global protein expression market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the protein expression market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The protein expression market includes revenue earned by instruments, expression kits, and systems. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global protein expression market is segmented - 1) By Protein Expression: Yeast Expression, Mammalian Expression, Algae Expression, Insect Expression, Bacterial Expression, Cell-free Expression 2) By End Use: Pharmaceutical And Biotechnological Companies, Academic Research, Contract Research Organizations 3) By Product: Reagents, Competent Cells, Expression vectors, Services, Instruments 4) By Application: Therapeutic, Industrial, Research

Protein labelling refers to the process of detecting or purifying the labelled protein and its binding partners by using the proper molecular labels. Most biological research uses one of three basic categories of protein labels: biotin, enzyme conjugates, or fluorescence probes. The main types of products in protein labelling are reagents, proteins, enzymes, probes or tags, and monoclonal antibodies. Monoclonal antibodies are created by cloning a single white blood cell. Every subsequent antibody generated in this manner may be traced back to a single parent cell. The different labelling methods include in-vitro labeling, and in-vivo labelling and are used in cell-based assays, fluorescence microscopy, immunological techniques, mass spectrometry, and protein microassays. The protein labelling market research report is one of a series of new reports from The Business Research Company that provides protein labelling market statistics, including the industry's global market size, regional shares, competitors with a protein labelling market share, detailed protein labelling market segments, market trends and opportunities, and any further data you may need to thrive in the protein labelling industry. This protein labelling market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global protein labelling market grew from $2.13 billion in 2022 to $2.35 billion in 2023 at a compound annual growth rate (CAGR) of 10.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The protein labelling market is expected to grow from $3.49 billion in 2027 at a CAGR of 10.4%. Increased spending on the R&D of proteomics and genomics is driving the growth of the protein labelling reagents market. Proteomics is the study of the overall protein content of a cell, tissue, or organism. Protein labelling methods before separation and analysis are essential during proteomic profiling approaches. For instance, the National Institutes of Health (NIH) of the United States, funded $37 billion for biomedical research. This funding is for life sciences research that supports study at a molecular level for the understanding of fundamental processes by which diseases develop, the identification of biomarkers that signal the presence of disease, or identification of genes or proteins responsible for the disease. The Novo Nordisk Foundation granted a grant of up to $1.5 million to the University of Copenhagen to establish a mass spectrometry facility, which marks a new and exciting step in protein research. Therefore, the increased spending on research and development of proteomics and genomics is driving the market. Drawbacks related to protein labelling techniques are expected to hinder the market. Label-free techniques are preferred over labelled techniques because of the drawbacks associated with them, such as wet-lab complexity and flexibility. While label-free samples can be measured without much preparation, wet lab pre-treatment is required for all labelling techniques. Samples must be labelled with metabolic (e.g. SILAC) or chemical (e.g. iTRAQ or TMT) reagents and the different conditions has to be combined. Therefore, label-free techniques are less prone to wet lab errors than labelling techniques. Label-free approaches have the advantage of being highly adaptable, even after the study has begun. New samples can be included at any time, but labelled approaches require the same number (n) of each condition. New samples may not be included in the study if they cannot be physically mixed and measured with the control. Labeled techniques such as the Super-SILAC approach reduce this problem but must also be carefully planned. These disadvantages are making label-free techniques preferable. Therefore, drawbacks associated with protein labeling techniques are expected to hinder the market. Companies in the protein labelling market are increasing their product innovation through strategic collaborations. To sustain in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated as well as academic and research institutions in this market by way of partnerships, in or out-licensing deals, this trend has been increasing over recent years. For instance, recombinant protein manufacturer enGenes Biotech GmbH (enGenes) announced a collaboration with ACIB GmbH for protein labeling. In January 2020, Abcam, a UK-based protein research tools producer and seller, announced its decision to acquire Expedeon's Proteomics and Immunology business, which includes Innova and TGR Biosciences. Expedeon technology supports a diverse set of labels, including enzymes, metals, oligos, and fluorescent proteins. Abcam will combine the newly acquired capture and conjugation technologies with its extensive antibody and protein expertise to expand and enhance its portfolio of off-the-shelf, and custom reagents and tools. Expedeon is a Germany-based manufacturer of protein discovery and analysis products used for protein and drug research. Major players in the protein labelling market are Thermo Fisher Scientific Inc., Merck KGaA, PerkinElmer, Inc., General Electric Company, F. Hoffmann-La Roche AG, AGILENT TECHNOLOGIES INC., BIO-RAD LABORATORIES, Kirkegaard & Perry Laboratories, LI-COR Inc. and Kaneka Corporation. North America was the largest region in the protein labeling market in 2022. The regions covered in the global protein labelling market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the protein labelling market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The protein labeling market includes revenues earned by entities by detecting or purifying the labelled protein and its binding partners. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global protein labelling market is segmented - 1) By Product: Reagents, Protein, Enzymes, Probes/ Tags, Monoclonal Antibodies 2) By Labeling Method: In-vitro Labeling, In-vivo Labeling 3) By Application: Cell Based-Assay, Fluorescence Microscopy, Immunological Techniques, Mass Spectrometry, Protein Micro Assay

Protein inhibitors refer to compounds that interfere with the steps directly involved in the production of new proteins in cells. Protein inhibitors operate at the ribosome level, benefiting from the significant variations between prokaryotic and eukaryotic ribosome architectures. The main product types of protein inhibitors are protein kinase inhibitors, monoclonal antibodies, and others. Monoclonal antibodies are laboratory-created molecules designed to act as substitute antibodies, restoring, enhancing, modifying, or mimicking the immune system's attack on unwanted cells, such as cancer cells. The protein inhibitors are used in the treatment of oncology, inflammatory diseases, and others, and are distributed by hospital pharmacies, independent pharmacies, and online pharmacies. The protein inhibitors market research report is one of a series of new reports from The Business Research Company that provides protein inhibitors market statistics, including protein inhibitors industry global market size, regional shares, competitors with a protein inhibitors market share, detailed protein inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the protein inhibitors industry. This protein inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global protein inhibitors market grew from $68.17 billion in 2022 to $74.3 billion in 2023 at a compound annual growth rate (CAGR) of 9.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The protein inhibitors market is expected to grow from $105.43 billion in 2027 at a CAGR of 9.1%. The increasing prevalence of chronic diseases is predicted to contribute to the growth of the protein inhibitors market over the forecast period. Chronic diseases such as cancer, cardiovascular diseases, and autoimmune diseases are becoming more prevalent. For instance, in May 2022, according to the World Health Organization, chronic diseases are expected to become the seventh leading cause of death globally by the end of 2030.In the USA, the number reached 157 million in 2020, with 87 million people having multiple conditions. Protein inhibitors are used for the treatment of these diseases attributing to fewer adverse effects and higher efficacy. Therefore, an increasing number of people with chronic diseases are anticipated to propel the demand for protein inhibitors market. The high cost of protein inhibitors used for cancer is anticipated to limit the growth of the protein inhibitors market shortly. Monoclonal antibodies are a type of protein made in the laboratory to bind substances in the body including cancer cells and are used to treat various types of cancer. Monoclonal antibody therapies are considered to be costlier when used for cancer. For instance, according to the National Center for Biotechnology Information, the average price of monoclonal antibodies was $96,731 for 34 monoclonal antibody indication combinations. Oncology and hematology monoclonal antibodies represented 40% of approved monoclonal antibody indication combinations, yet accounted for more than 85% of those priced at $100,000 or higher. The price of oncology or hematology monoclonal antibodies was $149,622 higher than those used in metabolic or cardiovascular disorders, $106,830 higher than in ophthalmology, $128,856 higher than in infectious diseases or allergies, and $98,981 higher than in immunology. Thus, the high cost of protein inhibitors including monoclonal antibodies for the treatment of cancer is expected to hinder the market’s growth. Companies in the protein inhibitors market are increasingly investing in various strategic initiatives such as partnerships and collaborations to develop new drugs to meet the market demand. Strategic collaborations and partnership agreements help companies to expand their existing product portfolio and geographical presence. For instance, in February 2020, Catalent, Inc., a USA-based provider of delivery technologies, drug manufacturing, gene therapies, biologics, and consumer healthcare products announced a partnership agreement with Zumutor Biologics Inc., an immune-oncology company based in the USA to manufacture ZM008, a monoclonal antibody targeting solid tumors. Moreover, in February 2021, Eli Lilly and Company, a USA-based pharmaceutical company, and Rigel Pharmaceuticals, Inc., a USA-based biotechnology company, announced a global exclusive license agreement and strategic collaboration to co-develop and commercialize Rigel's R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications, including autoimmune and inflammatory diseases. In June 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology company, acquired ReViral for $525 million. The acquisition strengthens Pfizer's commitment to creating both medications and vaccines to help fight the respiratory syncytial virus while also expanding its anti-infective portfolio (RSV). ReViral is a UK-based clinical-stage biopharmaceutical company pioneering in the discovery and development of innovative antiviral drugs for disorders brought on by the respiratory syncytial virus. Major players in the protein inhibitors market are Bayer AG, Astra Zeneca, Roche, Teva, Apotex, Novartis, GlaxoSmithKline, Pfizer, Boehringer Ingelheim, and F. Hoffmann-La Roche. North America was the largest region in the protein inhibitors market in 2022. The regions covered in the global protein inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the global protein inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The protein inhibitors market consists of sales of erythromycin, tetracycline, chloramphenicol, and aminoglycosides. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global protein inhibitors market is segmented - 1)By Product: Protein Kinase Inhibitors, Monoclonal Antibody, Other Products 2)By Application: Oncology, Inflamatory Diseases, Other Applications 3)By Distribution Channel: Hospital Pharmacies, Independent Pharmacies, Online Pharmacies

Protein purification and isolation refers to the procedures used to separate an interesting protein from its surroundings. In other words, from a cell culture created in a lab or from the other natural chemicals naturally surrounding the proteins in the natural niche in a host organism. This process helps to identify the existence of the protein from the source, based on differences in their properties. The main types of protein purification and isolation are instruments and consumables. The instruments are devices used to carry out protein purification and isolation processes that include extraction, precipitation, differential solubilization, ultracentrifugation, and chromatographic methods. The various technologies used are ultrafiltration, precipitation, preparative chromatography, electrophoresis, western blotting, dialysis and diafiltration and centrifugation and various end users include academic medical institutes, hospitals and diagnostic centers, pharmaceutical and biotechnology companies and contract research organizations. The applications include drug screening, protein-protein interaction studies, biomarker discovery, target identification, protein therapeutics, disease diagnostics and monitoring. The protein purification and isolation market research report is one of a series of new reports from The Business Research Company that provides protein purification and isolation market statistics, including protein purification and isolation industry global market size, regional shares, competitors with an protein purification and isolation market share, detailed protein purification and isolation market segments, market trends and opportunities, and any further data you may need to thrive in the protein purification and isolation industry. This protein purification and isolation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global protein purification and isolation market size grew from $7.77 billion in 2022 to $8.58 billion in 2023 at a compound annual growth rate (CAGR) of 10.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The protein purification and isolation market size is expected to grow to $12.44 billion in 2027 at a CAGR of 9.7%. An increase in spending by governments on research and development in pharmaceutical and biotechnology is expected to propel the growth of the protein purification and isolation market going forward. Research and development refer to gathering knowledge to create new products or discover new ways to improve their existing products and services. An increase in spending on research and development helps to develop advanced protein purification processes and also provides various other benefits such as purified growth factors of hormones, DNA polymerases, and reverse transcriptase. For instance, according to the Indian Brand Equity Foundation, an India-based export promotion agency, the Indian government has allocated USD 10.35 billion and the Department of Health Research has allocated USD 365.68 billion respectively towards the promotion of the pharma sector for the year 2021. Further, according to The Good Food Institute, a US-based alternative protein innovation organization, in 2021, the US department of agriculture and National science, a US-based food safety organization spent USD50 million on advancements in the development of alternative proteins. Therefore, the Increasing spending by governments on research and development in pharmaceutical and biotechnology is driving the growth of the protein purification and isolation markets. Technological advancements are a key trend gaining popularity in the protein purification and isolation market. Major companies operating in the market are focused on developing new technological innovations to gain a competitive advantage. For instance, in April 2021, Thermo Fisher Scientific, a US-based manufacturer of scientific instrumentation, and medical software services launched KingFisher Apex Purification System. It is a high-protein sample purification instrument designed for scientists who work on extracting DNA, proteins, and cells. This system helps in protein and cell isolation and provides a customized process for flexible, reproducible, and fast sample preparation without additional expense. With the help of automation technology, it provides error-free reports and produces high-quality nucleic acids and proteins. This protein purification device can process 24 to 96 samples in 25 to 65 minutes. In November 2021, Beximco Pharmaceuticals Ltd., a Bangladesh-based pharmaceutical company acquired Sanofi Bangladesh for an undisclosed amount. Through this acquisition, Beximco is expected to strengthen its position in key therapeutic areas to drive sustainable revenue and profit growth. Sanofi is a France-based healthcare company that is involved in protein purification, and manufacturing of medicines and vaccines. Major players in the protein purification and isolation market are Abcam PLC, Agilent Technologies Inc., Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., BioVision Inc., Norgen Biotek Corp., GE Healthcare, GEA Group AG, Expedeon Ltd., Creative Biostructure, Qiagen, Geno Technology Inc., The Merck Group, Labome, Promega Corporation, OPRL Biosciences Pvt.Ltd., Purolite, Takara Bio Inc., Roche Applied Science, and Sigma-Aldrich. North America was the largest region in the protein purification and isolation market in 2022. The regions covered in the protein purification and isolation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the protein purification and isolation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The protein purification and isolation market includes revenues earned by entities by isolating one or a few proteins from a complex mixture. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced.It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global protein purification and isolation market is segmented - 1) By Product: Instruments, Consumables 2) By Technology: Ultrafiltration, Precipitation, Preparative Chromatography, Electrophoresis, Western Blotting, Dialysis and Diafiltration, Centrifugation 3) By Application: Drug Screening, Protein-Protein Interaction Studies, Biomarker Discovery, Target Identification, Protein Therapeutics, Disease Diagnostics and Monitoring 4) By End User: Academic Medical Institutes, Hospitals and Diagnostic Centers, Pharmaceutical and Biotechnology Companies, Contract Research Organizations

Therapeutic proteins refer to pharmaceuticals that are genetically modified versions of human proteins that are found naturally. These powerful, quick-acting medications were developed in a lab for pharmaceutical usage. Therapeutic proteins have altered how diseases are treated since they are very effective in vivo. The main types of products in therapeutic proteins are insulin, fusion proteins, erythropoietin, interferon, human growth hormone, and follicle-stimulating hormone. Insulin is a peptide hormone produced by beta cells in the pancreatic cells that serves as the individual's primary anabolic hormone. It affects fat, carbohydrate, and protein metabolism by boosting glucose uptake from the blood into the fat, liver, and skeletal muscle cells. The different functions include enzymatic and regulatory activity, special targeting activity, vaccines, and protein diagnostics and are used in various applications such as metabolic disorders, immunologic disorders, haematological disorders, cancer, hormonal disorders, genetic disorders, and others. The therapeutic proteins market research report is one of a series of new reports from The Business Research Company that provides therapeutic proteins market statistics, including industry global market size, regional shares, competitors with a therapeutic proteins market share, detailed therapeutic proteins market segments, market trends and opportunities, and any further data you may need to thrive in the therapeutic proteins industry. This therapeutic proteins market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global therapeutic proteins market grew from $112.17 billion in 2022 to $125.74 billion in 2023 at a compound annual growth rate (CAGR) of 12.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The therapeutic proteins market is expected to grow from $200.43 billion in 2027 at a CAGR of 12.4%. The therapeutic proteins market is being driven by technological advancements in protein-based drug development. Therapeutic proteins cannot be synthesised chemically, they need to be produced by genetic engineering and recombinant DNA technology in living cells or organisms. Protein-engineering platform technologies such as glycoengineering, pegylation, Fc-fusion, albumin fusion, and albumin drug conjugation help to increase the production yield, product purity, circulating half-life, targeting, and functionality of therapeutic protein drugs. Belimumab, ipilimumab, taliglucerase alfa, albiglutide, and recombinant human coagulation factor IX are some therapeutic protein drugs developed using protein engineering technologies and approved by the FDA in the past five years. Increasing the number of biosimilar drugs on the global market will slow the growth of the therapeutic protein market. The patent expiration of therapeutic proteins such as monoclonal antibodies allows biosimilars to enter the market.For instance, in October 2022, Amneal Pharmaceuticals, Inc., a US-based generics and specialty pharmaceutical company, launched ALYMSYS® (bevacizumab-maly) in the United States. These cost-effective treatments, similar to the original biologics, decline the revenue and sales of therapeutic proteins. Monoclonal antibody drug approvals are increasing in the protein therapeutic segment. Chronic diseases such as cancer and immunological disorders are well treated with monoclonal antibodies. Monoclonal antibodies are a dominant and well-established product class in the protein therapeutic segment, with more safety and immunogenicity than antibodies. By overcoming the problems associated with previous antibody drugs, cell-based expression systems, such as the Chinese hamster ovary (CHO) mammalian cell expression system, have increased the productivity of monoclonal antibodies.In the last five years, the FDA has approved 213 drugs, among which 44 are monoclonal antibodies. For instance, twelve monoclonal antibodies were approved by FDA for the treatment of cancer and immunological disorders. In the United States, therapeutic protein drug manufacturers file a biologics application (BLA) with the FDA for product approval. The drug that is approved through BLA must be proven to be safe, pure, and potent.FDA consolidated review of most therapeutic proteins in the Center for Drug Evaluation and Research (CDER). In European Union, biologics are regulated by Committee for Medicinal Products for Human Use (CHMP) for marketing authorization. Eli Lilly and Company, a US-based pharmaceutical company, paid $1 billion for Protomer Technologies Inc. in July 2021.Lilly is delighted to add protomer’s breakthrough technology to its diabetes pipeline through this acquisition, since the company’s glucose-sensing insulin program, which is based on its proprietary molecular engineering of protein sensors (MEPS) platform, is exhibiting great potential. Protomer Technologies Inc. is a US-based company that specialises in next-generation protein therapies that can detect molecular activators in the body and are currently being developed. Major players in the therapeutic proteins market are Abbott Laboratories, Amgen Inc., Baxter International Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Pfizer Inc., Johnson & Johnson, and Merck & Co. Inc., Novo Nordisk A/S, and Sanofi. North America was the largest region in the therapeutic proteins market in 2022. The regions covered in the global therapeutic proteins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the therapeutic proteins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The therapeutic proteins market consists of sales of antibody-based drugs, FC fusion proteins, and anticoagulants. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global therapeutic protein market is segmented - 1) By Product Type: Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, Follicle Stimulating Hormone 2) By Application: Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders, Other Applications 3) By Function: Enzymatic and Regulatory Activity, Special Targeting Activity, Vaccines, Protein Diagnostics

C-reactive protein testing measures the level of c-reactive protein (CRP) in the blood. CRP is a liver-produced protein released into the bloodstream due to inflammation. When the body is wounded or infected, inflammation is the body's way of protecting the tissues. CRP testing is generally used to diagnose inflammation caused due to an infection. The main types of assays in c-reactive protein testing market are enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA) and immunoturbidimetric assays. The enzyme-linked immunosorbent assay (ELISA) is used to measure CRP (c-reactive protein). C-reactive protein (CRP) ELISA test offers quantitative measurement of human c-reactive protein in serum to help in the follow-up of rheumatic fever, inflammatory processes, and others. Elisa is a biological assay that measures antibodies, antigens, proteins, and glycoproteins. The c-reactive protein testing is mainly used in clinics, hospitals and diagnostic laboratories for diseases such as diabetes, rheumatoid arthritis, cardiovascular disease, inflammatory bowel disease, cancer and others. The c-reactive protein testing market research report is one of a series of new reports from The Business Research Company that provides c-reactive protein testing market statistics, including c-reactive protein testing industry global market size, regional shares, competitors with an c-reactive protein testing market share, detailed c-reactive protein testing market segments, market trends and opportunities, and any further data you may need to thrive in the c-reactive protein testing industry. This c-reactive protein testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global c-reactive protein testing market size grew from $3.28 billion in 2022 to $3.37 billion in 2023 at a compound annual growth rate (CAGR) of 2.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The c-reactive protein testing market size is expected to grow to $3.67 billion in 2027 at a CAGR of 2.2%. The increase in cases of cardiovascular diseases (CVD) are expected to propel the growth of the c-reactive protein testing market. Cardiovascular diseases refer to heart conditions such as diseased vessels, structural problems, and blood clots. The exact cause of CVD is uncertain, but numerous factors can increase the risk of developing it. One such factor is the behavioral risk caused due to unbalanced eating, lack of physical activity, smoking, and alcohol use, which results in an accumulation of fatty deposits inside the arteries (atherosclerosis), resulting in an increased risk of blood clots. These behavioral risks result in elevated blood pressure, glucose, blood lipids, weight gain, and obesity. The increasing cases of cardiovascular diseases invites the need for c-reactive protein testing to diagnose or predict the chance of having cardiovascular problems at least as well as cholesterol levels. For instance, according to the key facts published in June 2021 by the WHO (World Health Organization), cardiovascular diseases are the leading cause of death worldwide. Around 17.9 million die every year due to CVD, accounting for 32% of all global deaths. Therefore, the increasing cases of cardiovascular diseases will drive the c-reactive protein testing market. Technological advancement in measuring devices is a key trend in the c-reactive protein testing market. Major companies operating in the c-reactive protein testing market are focused on providing technologically advanced solutions to strengthen their market position. These companies are implementing next-generation c-reactive testing technologies into their testing methods and advanced solutions that provide benefits such as maximum output and multiple usages. For instance, in February 2022, Aidian, a Finnish-based diagnostic tests, and test solutions company, released the QuikRead go wrCRP & wrCRP+Hb kits. The kit consistently produces two results, a wide range of CRP and Hb, from a single sample with one analysis. The wide-range CRP test permits CRP readings to assess conditions such as neonatal sepsis, predict disease severity in COPD (chronic obstructive pulmonary disease), and assist in cardiovascular risk assessment. In October 2021, Abcam, a UK-based producer, distributor, and marketer of protein research tools, acquired BioVision Inc., for $340 million. This acquisition is expected to increase Abcam's immunoassay capacity in Eugene, OR, by expanding the kits and assay portfolio. In addition to accelerating strategy execution, the company will also focus on in-house innovation and product development in the complementary biochemical and cell-based assay markets. BioVision Inc. is a US-based innovator and distributor of life science research tools, including CRP ELISA kits, to biopharma, diagnostic, and academic customers. Major players in the c-reactive protein testing market are Thermo Fisher Scientific Inc., F Hoffmann-La Roche Ltd., Danaher, Quest Diagnostics, Siemens Healthineers, Abbott Laboratories, Laboratory Corporation of America Holdings, Merck, Abaxis Inc. (Zoetis), Ortho Clinical Diagnostics, Getein Biotech, Horiba, Randox Laboratories, Boditech Med, Eurolyser Diagnostica GmbH, Aidian, EKF Diagnostics, SD Biosensor Inc., Abcam plc, and Bio-Techne. North America was the largest region in the c-reactive protein testing market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the c-reactive protein testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the c-reactive protein testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The c-reactive protein testing market includes revenues earned by entities by devices and reagents. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.  The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global c-reactive protein testing market is segmented - 1) By Assay Type: Enzyme-Linked Immunosorbent Assay (ELISA), Chemiluminescence Immunoassay (CLIA), Immunoturbidimetric Assays 2) By End Use: Clinics, Hospitals, Diagnostic Laboratories 3) By Application: Diabetes, Rheumatoid Arthritis, Cardiovascular Disease, Inflammatory Bowel Disease, Cancer, Other Applications

The study of genomes is called genomics. Single-cell genomics is an innovative method of classifying individual cells from a tissue sample, capable of defining unique traits and identifying rare cell types. Genomics is used in different fields of study, such as intragenomic phenomena such as pleiotropy, epistasis, heterosis, and other interactions between loci and alleles within the genome. The main product types of genomics are instrument (including systems, service contract and software), reagents (including reagents and consumables). A reagent is a substance or compound that is added to a system in order to produce a chemical reaction or to determine whether or not a reaction occurred. The different processes include cell isolation, sample preparation, and genomic analysis that are used by academic institutes, biopharmaceutical companies, and clinical research institutes. The genomics market research report is one of a series of new reports from The Business Research Company that provides genomics market statistics, including genomics industry global market size, regional shares, competitors with a genomics market share, detailed genomics market segments, market trends and opportunities, and any further data you may need to thrive in the genomics industry. This genomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global genomics market grew from $32.56 billion in 2022 to $38.45 billion in 2023 at a compound annual growth rate (CAGR) of 18.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The genomics market is expected to grow from $76.28 billion in 2027 at a CAGR of 18.7%. Rising government funds for research on genomics drives the growth of the single-cell genomics market. The government funding focuses on efforts to resolve the complexity of the human genome, define the genomic basis of human health and disease, and ensure that genomics is used safely to enhance patient care and benefit society through government, public and private institutions. For instance, in April 2021, US government announced an investment of $1.7 billion for improving the detection, monitoring, and reduction of SARS-CoV-2 variants and to improve infrastructure for further genomic sequencing. The funds were announced through the American Rescue Plan. The funding would be distributed through three separate initiatives at different times. The technology limitation in single-cell genomics hinders the growth of the single-cell genomics market. Due to cost and technical constraints, the use of genetic sequencing to better target and treat rare and chronic diseases was largely out of reach for most health care organizations. Therefore, limiting the market growth. Companies are investing in new product launches to increase their revenue and expand their consumer base and also for gaining a competitive edge over their rivals. For instance, in June 2021, QIAGEN, a Netherlands-based provider of sample and assay technologies for molecular diagnostics, applied testing, academic, and pharmaceutical research, has announced the release of the QIAprep& CRISPR Kit and CRISPR Q-Primer Solutions, which enable researchers to analyse edited genetic material with unprecedented speed and efficiency to determine how their interventions have changed the function of the DNA sequence in question. In November 2021, Myriad Genetics, an American genetic testing company, acquired Gateway Genomics, for $67.5 million. The acquisition is an effort by Myriad towards their goal of bringing relevant genetic information to consumers to add value to their lives. Gateway Genomics is an American personal genomics company and manufacturer of the SneakPeek® early gender DNA test for detecting a baby’s gender. Major players in the genomics market are 10X Genomics, Qiagen NV, Fluidigm Corporation, Johnson & Johnson Private Limited, Zephyrus Biosciences Inc., Illumina Inc., Affymetrix, Angle PLC., Denovo Sciences Inc., Diagnologix LLC., DNA Electronics Ltd., Enumeral, Epic Sciences, Kellbenx Inc., Resolution Bio Science Inc., Wafergen Bio-systems Inc., Yikon Genomics Co. Ltd., Thermo Fisher Scientific Inc., CellBio, Beckman Coulter, Becton Dickinson, Bio-Rad, Carl Zeiss Microscopy, Cell Microsystems, Cellsee Diagnostics, CellSorter, Cytena, CytoTrack, Dolomite Bio, Agilent Technologies Inc., and Fluxion Biosciences. North America was the largest region in the genomics market in 2022. Western Europe was the second largest region in the global genomics market. The regions covered in the global genomics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the genomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The genomics market consists of sales of genomics such as structural genomes, functional genomes, mutation genomics and comparative genomics that are used for drug discovery and development. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global genomics market is segmented - 1) By Product Type: Instrument (Including Systems, Service Contract And Software), Reagents (Including Reagents And Consumables) 2) By Process: Cell Isolation, Sample Preparation, Genomic Analysis 3) By End User: Academic Institutes, Biopharmaceutical Companies, Clinical Research Institutes